MCID: CHR090
MIFTS: 74

Chronic Lymphocytic Leukemia malady

Categories: Genetic diseases, Rare diseases, Cancer diseases, Blood diseases, Immune diseases

Aliases & Classifications for Chronic Lymphocytic Leukemia

About this section
Sources:
11Disease Ontology, 13DISEASES, 24GeneTests, 27GTR, 30ICD10, 31ICD10 via Orphanet, 32ICD9CM, 35LifeMap Discovery®, 37MedGen, 38MedlinePlus, 39MeSH, 40MESH via Orphanet, 45NCIt, 48NIH Rare Diseases, 50Novoseek, 54Orphanet, 62SNOMED-CT, 68UMLS, 69UMLS via Orphanet, 70UniProtKB/Swiss-Prot
See all MalaCards sources

Aliases & Descriptions for Chronic Lymphocytic Leukemia:

Name: Chronic Lymphocytic Leukemia 35 11 48 24 38 13 68
Cll 11 48 24 70
B-Cell Chronic Lymphocytic Leukemia 11 54 70
Leukemia, Chronic Lymphocytic 24 70 27
B-Cell Chronic Lymphoid Leukemia 11 54
Chronic Lymphatic Leukemia 11 70
Small Lymphocytic Lymphoma 54 68
Lymphoplasmacytic Leukemia 11 68
 
Leukemia, Lymphocytic, Chronic, B-Cell 39
Familial Chronic Lymphocytic Leukemia 24
Lymphocytic Leukemia Chronic B-Cell 50
Leukemia, Lymphocytic, Chronic 48
Leukemia Lymphocytic Chronic 50
Lymphoma Small Lymphocytic 50
Chronic Lymphoid Leukemia 70
B-Cll 54

Characteristics:

Orphanet epidemiological data:

54
b-cell chronic lymphocytic leukemia:
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-5/10000 (Europe),1-9/100000 (France); Age of onset: Adult

Classifications:



External Ids:

Disease Ontology11 DOID:1040
ICD1030 C91.1, C91.10
ICD9CM32 204.1
MeSH39 D015451
NCIt45 C3163
Orphanet54 ORPHA67038
ICD10 via Orphanet31 C91.1
MESH via Orphanet40 D015451
UMLS via Orphanet69 C0023434
MedGen37 C0023434

Summaries for Chronic Lymphocytic Leukemia

About this section
NIH Rare Diseases:48 Chronic lymphocytic leukemia (CLL) is a cancer of the lymphocytes (a type of white blood cell) that begins in the stem cells of the bone marrow and then invades the blood. Overtime, CLL may also spread to the lymph nodes and other organs including the liver, spleen and lungs. It occurs when the stem cells that make lymphocytes become out of control and produce increasing amounts of abnormal lymphocytes (also called leukemic cells). Eventually, these abnormal cells replace normal lymphocytes and can crowd out other types of normal blood cells, leading to the features of the condition. Early signs and symptoms of CLL may include fatigue, weight loss, loss of appetite, fever, night sweats and/or frequent infections. The exact underlying cause of CLL is unknown; however, approximately 5% of affected people have other family members with the condition, which suggests there may be a genetic component in rare cases. The best treatment depends on many factors including the stage of the condition, the age of the affected person, the blood cell counts, whether the CLL has recurred, and the signs and symptoms present in each person. Last updated: 12/27/2014

MalaCards based summary: Chronic Lymphocytic Leukemia, also known as cll, is related to hemolytic anemia and leukemia, acute myeloid, and has symptoms including chest pain, chest pain and fatigue. An important gene associated with Chronic Lymphocytic Leukemia is CCND1 (Cyclin D1), and among its related pathways are DNA damage_ATM/ATR regulation of G1/S checkpoint and Integrated Breast Cancer Pathway. The drugs immunoglobulins, intravenous and cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone and bone marrow, and related mouse phenotypes are Increased viability with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor).

Disease Ontology:11 A lymphoblastic leukemia characterized by over production of B-cells and their accumulation in bone marrow and blood.

MedlinePlus:38 Leukemia is cancer of the white blood cells. white blood cells help your body fight infection. your blood cells form in your bone marrow. in leukemia, the bone marrow produces abnormal white blood cells. these cells crowd out the healthy blood cells, making it hard for blood to do its work. in chronic lymphocytic leukemia (cll), there are too many lymphocytes, a type of white blood cell. cll is the second most common type of leukemia in adults. it often occurs during or after middle age, and is rare in children. usually cll does not cause any symptoms. if you have symptoms, they may include painless swelling of the lymph nodes in the neck, underarm, stomach, or groin fatigue pain or a feeling of fullness below the ribs fever and infection weight loss tests that examine the blood, bone marrow, and lymph nodes diagnose cll. your doctor may choose to just monitor you until symptoms appear or change. treatments include radiation therapy, chemotherapy, surgery to remove the spleen, and targeted therapy. targeted therapy uses substances that attack cancer cells without harming normal cells. nih: national cancer institute

UniProtKB/Swiss-Prot:70 Leukemia, chronic lymphocytic: A chronic leukemia in which functionally incompetent B-lymphocytes progressively accumulate in the bone marrow, blood, and lymphoid tissues. The clinical evolution of the disorder is heterogeneous, with some patients having indolent disease and others having aggressive disease and short survival.

Wikipedia:71 B-cell chronic lymphocytic leukemia (B-CLL), also known as chronic lymphoid leukemia (CLL), is the most... more...

Related Diseases for Chronic Lymphocytic Leukemia

About this section

Diseases in the Acute Lymphocytic Leukemia family:

Leukemia, Chronic Lymphocytic 3 Leukemia, Chronic Lymphocytic 1
Leukemia, Chronic Lymphocytic 2 Adult Acute Lymphocytic Leukemia
chronic lymphocytic leukemia

Diseases related to Chronic Lymphocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 272)
idRelated DiseaseScoreTop Affiliating Genes
1hemolytic anemia31.8CCND1, CD38, CD5, MCL1, PAX5, TP53
2leukemia, acute myeloid30.7CD38, CD5, MCL1, TP53
3leukemia, chronic lymphocytic 312.1
4leukemia, chronic lymphocytic 112.1
5leukemia, chronic lymphocytic 212.1
6postgerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma12.0
7pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma12.0
8cll/sll11.8
9t-cell prolymphocytic leukemia11.8
10leukemia11.7
11prolymphocytic leukemia11.3
12chronic leukemia11.3
13chromosome 13q14 deletion syndrome11.0ATM, BCL2, CD38, CD5, FCER2, IGHM
14clear cell acanthoma11.0ATM, CD38, CD5, TP53
15benign angiitis of the central nervous system11.0CD38, CD5, FCER2, MS4A1, TP53, ZAP70
16pneumonic plague11.0ATM, CD38, CD5, MS4A1, ZAP70
17acral lentiginous melanoma11.0ATM, CCND1, CD38, CD5, TP53, ZAP70
18leukemia, b-cell, chronic11.0
19megakaryocytic leukemia11.0ATM, CCND1, CD5, MCL1, TP53
20novak syndrome11.0BCL2, CCND1, TP53
21drug-induced hepatitis11.0BCL2, CCND1, CD5, TP53
22lysosomal storage disease11.0BCL2, CCND1
23nasopharyngeal carcinoma10.9ATM, BCL2, TP53
24stenosis of lacrimal sac10.9BCL2, CCND1, TP53
25t-cell large granular lymphocyte leukemia10.9
26aneurysm of sinus of valsalva10.9IGHM, MS4A1
27melanoma metastasis10.9BCL2, CCND1, CD5
28solitary plasmacytoma of chest wall10.9CCND1, CD38, CD5
29gastric cancer10.9BCL2, CCND1, TP53
30brittle bone syndrome lethal type10.9ATM, CCND1, TP53
31lymphoma, malt, somatic10.9BCL2, CCND1, CD5
32pyridoxine-responsive sideroblastic anemia10.9ATM, BCL2, BCL3, CCND1
33monkeypox10.9BCL2, CD5
34organ system benign neoplasm10.9CCND1, CD38, CD5, MCL1, PAX5, TP53
35smoking as a quantitative trait locus 110.9ATM, BCL2, BCL3, CCND1, CD38, CD5
36metabolic acidosis10.9CD38, CD5, PAX5
37testis refractory cancer10.8BCL2, CD5
38bipolar disorder10.8BCL3, CCND1, CD5, PAX5, TP53
39gastroesophageal reflux10.8CD38, ZAP70
40acute motor axonal neuropathy10.8BCL2, CD5
41gray zone lymphoma10.8CCND1, CD5, PAX5
42lymphoma10.7
43amyloid tumor10.7ATM, CCND1
44solitary osseous plasmacytoma10.7BCL2, CCND1
45pediatric t-cell leukemia10.6BCL2, IGHM
46cpt deficiency, hepatic, type ia10.6CCND1, CD38, IGHG1, MCL1, TP53
47leukoencephalopathy palmoplantar keratoderma10.5CCND1, CD38, IGHG1
48bone development disease10.5CCND1, CD38, IGHG1, MCL1
49richter's syndrome10.4
50autoimmune hemolytic anemia10.3

Graphical network of the top 20 diseases related to Chronic Lymphocytic Leukemia:



Diseases related to chronic lymphocytic leukemia

Symptoms & Phenotypes for Chronic Lymphocytic Leukemia

About this section

UMLS symptoms related to Chronic Lymphocytic Leukemia:


chest pain, fatigue

GenomeRNAi Phenotypes related to Chronic Lymphocytic Leukemia according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00250-A-311.3ATM, BCL2, FCER2, MCL1, POT1, TP53
2GR00250-A-110.5ATM, BCL2, CCND1, CD38, MCL1, POT1

MGI Mouse Phenotypes related to Chronic Lymphocytic Leukemia according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000539711.3ATM, BCL2, BCL3, CCND1, CD38, CD5
2MP:000538711.3ATM, BCL2, BCL3, CCND1, CD38, CD5

Drugs & Therapeutics for Chronic Lymphocytic Leukemia

About this section

FDA approved drugs:

(show all 9)
id Drug Name Active Ingredient(s)16 Company Approval Date
1
Arzerra16 44 OFATUMUMAB GlaxoSmithKline October 2009
FDA Label: Arzerra
Disease/s that Drug Treats:chronic lymphocytic leukemia
Indications and Usage:16 ARZERRA (ofatumumab) is a CD20-directed cytolytic monoclonal antibodyindicated: in combination with chlorambucil, for the treatment of previouslyuntreated patients with chronic lymphocytic leukemia (CLL) for whomfludarabine-based therapy is considered inappropriate. (1.1) for the treatment of patients with CLL refractory to fludarabine andalemtuzumab. (1.2)
DrugBank Targets:14 no entry
Mechanism of Action:16 
Target: B-cell
Action: promotes lysis
FDA: Ofatumumab binds specifically to both the small and large extracellular loops of the CD20402 molecule. The CD20 molecule is expressed on normal B lymphocytes (pre-B- to mature403 B-lymphocyte) and on B-cell CLL. The CD20 molecule is not shed from the cell surface and is404 not internalized following antibody binding.405406 The Fab domain of ofatumumab binds to the CD20 molecule and the Fc domain mediates407 immune effector functions to result in B-cell lysis in vitro. Data suggest that possible408 mechanisms of cell lysis include complement-dependent cytotoxicity and antibody-dependent,409 cell-mediated cytotoxicity.
2
Campath16 44 ALEMTUZUMAB Berlex Laboratories May 2001
FDA Label: Campath
Disease/s that Drug Treats:Leukemia
Indications and Usage:16 LEMTRADA is a CD52-directed cytolytic monoclonal antibody indicated dizziness, abdominal pain, flushing, and vomiting. (6.1) for the treatment of patients with relapsing forms of multiple sclerosis(MS).
DrugBank Targets:14 1. CAMPATH-1 antigen;2. Low affinity immunoglobulin gamma Fc region receptor III-B;3. Complement C1r subcomponent;4. Complement C1q subcomponent subunit A;5. Complement C1q subcomponent subunit B;6. Complement C1q subcomponent subunit C;7. Low affinity immunoglobulin gamma Fc region receptor III-A;8. High affinity immunoglobulin gamma Fc receptor I;9. Low affinity immunoglobulin gamma Fc region receptor II-a;10. Low affinity immunoglobulin gamma Fc region receptor II-b;11. Low affinity immunoglobulin gamma Fc region receptor II-c;;
Mechanism of Action:16 
Target: CD52 antigen
Action: after binding, induces cell lysis
FDA: The precise mechanism by which alemtuzumab exerts its therapeutic effects in multiple490 sclerosis is unknown but is presumed to involve binding to CD52, a cell surface antigen491 present on T and B lymphocytes, and on natural killer cells, monocytes, and492 macrophages. Following cell surface binding to T and B lymphocytes, alemtuzumab493 results in antibody-dependent cellular cytolysis and complement-mediated lysis.
3
Clolar16 44 CLOFARABINE Genzyme December, 2004
FDA Label: Clolar
Disease/s that Drug Treats:Lymphoblastic Leukemia
Indications and Usage:16 Clolar (clofarabine) injection is a purine nucleoside metabolic inhibitorindicated for the treatment of pediatric patients 1 to 21 years old with relapsedor refractory acute lymphoblastic leukemia after at least two prior regimens.This indication is based upon response rate. There are no trials verifying animprovement in disease-related symptoms or increased survival with Clolar.(1)
DrugBank Targets:14 1. DNA polymerase alpha catalytic subunit;2. Ribonucleoside-diphosphate reductase large subunit;3. DNA
Mechanism of Action:16 
Target: ribonucleotide reductase
Action: inhibitor
FDA: Clofarabine is sequentially metabolized intracellularly to the 5’-monophosphate metabolite bydeoxycytidine kinase and mono- and di-phospho-kinases to the active 5’-triphosphate metabolite.Clofarabine has affinity for the activating phosphorylating enzyme, deoxycytidine kinase, equalto or greater than that of the natural substrate, deoxycytidine. Clofarabine inhibits DNA synthesisby decreasing cellular deoxynucleotide triphosphate pools through an inhibitory action onribonucleotide reductase, and by terminating DNA chain elongation and inhibiting repair throughincorporation into the DNA chain by competitive inhibition of DNA polymerases. The affinity ofclofarabine triphosphate for these enzymes is similar to or greater than that of deoxyadenosinetriphosphate. In preclinical models, clofarabine has demonstrated the ability to inhibit DNArepair by incorporation into the DNA chain during the repair process. Clofarabine 5’-triphosphate also disrupts the integrity of mitochondrial membrane, leading to the release of thepro-apoptotic mitochondrial proteins, cytochrome C and apoptosis-inducing factor, leading toprogrammed cell death.Clofarabine is cytotoxic to rapidly proliferating and quiescent cancer cell types in vitro.
4
Gazyva16 44 OBINUTUZUMAB Genentech October of 2013
FDA Label: Gazyva
Disease/s that Drug Treats:previously untreated chronic lymphocytic leukemia
Indications and Usage:16 GAZYVA (obinutuzumab) is a CD20-directed cytolytic antibody and isindicated, in combination with chlorambucil, for the treatment of patients withpreviously untreated chronic lymphocytic leukemia. (1, 14)
DrugBank Targets:14 1. B-lymphocyte antigen CD20
Mechanism of Action:16 
Target: CD20 antigen expressed on the surface of pre B- and mature B-lymphocytes
Action: engager of immune cells and/or activator of intracellular death signaling pathways and/or activator of the complement cascade
FDA: Obinutuzumab is a monoclonal antibody that targets the CD20 antigen expressed on the surfaceof pre B- and mature B-lymphocytes. Upon binding to CD20, obinutuzumab mediates B-celllysis through (1) engagement of immune effector cells, (2) by directly activating intracellulardeath signaling pathways and/or (3) activation of the complement cascade. The immune effectorcell mechanisms include antibody-dependent cellular cytotoxicity and antibody-dependentcellular phagocytosis.
5
Imbruvica16 44 IBRUTINIB Pharmacyclics November of 2013/ February 2014
FDA Label: Imbruvica
Disease/s that Drug Treats:mantle cell lymphoma/chronic lymphocytic leukemia
Indications and Usage:16 IMBRUVICA is a kinase inhibitor indicated for the treatment of patients with: Mantle cell lymphoma (MCL) who have received at least one priortherapy (1.1).Accelerated approval was granted for this indication based on overallresponse rate. Continued approval for this indication may be contingentupon verification of clinical benefit in confirmatory trials. Chronic lymphocytic leukemia (CLL) who have received at least oneprior therapy (1.2). Chronic lymphocytic leukemia with 17p deletion (1.3). Waldenström’s macroglobulinemia (WM) (1.4).
DrugBank Targets:14 1. Tyrosine-protein kinase BTK
Mechanism of Action:16 
Target: Bruton's tyrosine kinase (Btk)
Action: selective inhibitor
FDA: Ibrutinib is a small-molecule inhibitor of BTK. Ibrutinib forms a covalent bond with a cysteineresidue in the BTK active site, leading to inhibition of BTK enzymatic activity. BTK is asignaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways. BTK’srole in signaling through the B-cell surface receptors results in activation of pathways necessaryfor B-cell trafficking, chemotaxis, and adhesion. Nonclinical studies show that ibrutinib inhibitsmalignant B-cell proliferation and survival in vivo as well as cell migration and substrateadhesion in vitro.
6
Revlimid16 44 LENALIDOMIDE Celgene June 2013
FDA Label: Revlimid
Disease/s that Drug Treats:mantle cell lymphoma
Indications and Usage:16 REVLIMID is a thalidomide analogue indicated for the treatment of patientswith: Multiple myeloma (MM), in combination with dexamethasone (1.1). Transfusion-dependent anemia due to low- or intermediate-1-riskmyelodysplastic syndromes (MDS) associated with a deletion 5qabnormality with or without additional cytogenetic abnormalities (1.2). Mantle cell lymphoma (MCL) whose disease has relapsed or progressedafter two prior therapies, one of which included bortezomib (1.3).Limitations of Use: REVLIMID is not indicated and is not recommended for the treatmentof patients with chronic lymphocytic leukemia (CLL) outside ofcontrolled clinical trials (1.4).
DrugBank Targets:14 1. Protein cereblon;2. Tumor necrosis factor ligand superfamily member 11;3. Cadherin-5;4. Prostaglandin G/H synthase 2
Mechanism of Action:16 
Target: T cells and natural killer cells/ pro-inflammatory cytokines by monocytes
Action: activator/inhibitor
FDA: Lenalidomide is an analogue of thalidomide with immunomodulatory, antiangiogenic, and antineoplastic properties. Lenalidomide inhibitsproliferation and induces apoptosis of certain hematopoietic tumor cells including multiple myeloma, mantle cell lymphoma, and del (5q)myelodysplastic syndromes in vitro. Lenalidomide causes a delay in tumor growth in some in vivo nonclinical hematopoietic tumor modelsincluding multiple myeloma. Immunomodulatory properties of lenalidomide include activation of T cells and natural killer (NK) cells, increasednumbers of NKT cells, and inhibition of pro-inflammatory cytokines (e.g., TNF-α and IL-6) by monocytes. In multiple myeloma cells, thecombination of lenalidomide and dexamethasone synergizes the inhibition of cell proliferation and the induction of apoptosis.
7
Rituxan16 44 RITUXIMAB Biogen IDEC, Genentech November 1997
FDA Label: Rituxan
Disease/s that Drug Treats:non-hodgkin's lymphoma
Indications and Usage:16 Rituxan® (rituximab) is a CD20-directed cytolytic antibody indicated for thetreatment of patients with: Non-Hodgkin’s Lymphoma (NHL) (1.1) Chronic Lymphocytic Leukemia (CLL) (1.2) Rheumatoid Arthritis (RA) in combination with methotrexate in adultpatients with moderately-to severely-active RA who have inadequateresponse to one or more TNF antagonist therapies (1.3) Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) andMicroscopic Polyangiitis (MPA) in adult patients in combination withglucocorticoids (1.4)Limitations of Use: Rituxan is not recommended for use in patients withsevere, active infections (1.5).
DrugBank Targets:14 1. Low affinity immunoglobulin gamma Fc region receptor III-B;2. Complement C1r subcomponent;3. Complement C1q subcomponent subunit A;4. Complement C1q subcomponent subunit B;5. Complement C1q subcomponent subunit C;6. Low affinity immunoglobulin gamma Fc region receptor III-A;7. Complement C1s subcomponent;8. High affinity immunoglobulin gamma Fc receptor I;9. Low affinity immunoglobulin gamma Fc region receptor II-a;10. Low affinity immunoglobulin gamma Fc region receptor II-b;11. Low affinity immunoglobulin gamma Fc region receptor II-c;12. B-lymphocyte antigen CD20
Mechanism of Action:16 
Target: CD20 antigen expressed on the surface ofpre-B and mature B-lymphocytes
Action: mediator of B-cell lysis through different possible types of cytotoxicity
FDA: Rituximab is a monoclonal antibody that targets the CD20 antigen expressed on the surface ofpre-B and mature B-lymphocytes. Upon binding to CD20, rituximab mediates B-cell lysis. Possiblemechanisms of cell lysis include complement dependent cytotoxicity (CDC) and antibody dependentcell mediated cytotoxicity (ADCC). The antibody induced apoptosis in the DHL 4 human B celllymphoma cell line.B cells are believed to play a role in the pathogenesis of rheumatoid arthritis (RA) and associatedchronic synovitis. In this setting, B cells may be acting at multiple sites in theautoimmune/inflammatory process, including through production of rheumatoid factor (RF) andother autoantibodies, antigen presentation, T-cell activation, and/or proinflammatory cytokineproduction.
8
Treanda16 44 BENDAMUSTINE HYDROCHLORIDE Cephalon October 2008
FDA Label: Treanda
Disease/s that Drug Treats:Chronic lymphocytic leukemia and B-cell non-Hodgkin’s lymphoma
Indications and Usage:16 TREANDA is an alkylating drug indicated for treatment of patients with: Chronic lymphocytic leukemia (CLL). Efficacy relative to first linetherapies other than chlorambucil has not been established. (1.1) Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed duringor within six months of treatment with rituximab or a rituximab-containingregimen. (1.2)
DrugBank Targets: -
Mechanism of Action:16 
Target: -
Action: -
FDA: Bendamustine is a bifunctional mechlorethamine derivative containing a purine-like benzimidazole ring.Mechlorethamine and its derivatives form electrophilic alkyl groups. These groups form covalent bonds with electronrichnucleophilic moieties, resulting in interstrand DNA crosslinks. The bifunctional covalent linkage can lead to celldeath via several pathways. Bendamustine is active against both quiescent and dividing cells. The exact mechanism ofaction of bendamustine remains unknown.
9
Zydelig16 44 IDELALISIB Gilead July 2014
FDA Label: Zydelig
Disease/s that Drug Treats:relapsed CLL, follicular B-cell NHL and small lymphocytic lymphoma
Indications and Usage:16 Zydelig is a kinase inhibitor indicated for the treatment of patients with: Relapsed chronic lymphocytic leukemia (CLL), in combination withrituximab, in patients for whom rituximab alone would be consideredappropriate therapy due to other co-morbidities. (1.1) Relapsed follicular B-cell non-Hodgkin lymphoma (FL) in patientswho have received at least two prior systemic therapies. (1.2) Relapsed small lymphocytic lymphoma (SLL) in patients who havereceived at least two prior systemic therapies. (1.3)Accelerated approval was granted for FL and SLL based on overallresponse rate. Improvement in patient survival or disease relatedsymptoms has not been established. Continued approval for theseindications may be contingent upon verification of clinical benefit inconfirmatory trials.
DrugBank Targets:14 1. Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta isoform (P110δ)
Mechanism of Action:16 
Target: PI3Kδ kinase
Action: inhibitor
FDA: Idelalisib is an inhibitor of PI3Kδ kinase, which is expressed in normal and malignant Bcells.Idelalisib induced apoptosis and inhibited proliferation in cell lines derived frommalignant B-cells and in primary tumor cells. Idelalisib inhibits several cell signalingpathways, including B-cell receptor (BCR) signaling and the CXCR4 and CXCR5signaling, which are involved in trafficking and homing of B-cells to the lymph nodes andbone marrow. Treatment of lymphoma cells with idelalisib resulted in inhibition ofchemotaxis and adhesion, and reduced cell viability.

Drugs for Chronic Lymphocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 606)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Methylprednisoloneapproved, vet_approvedPhase 4, Phase 3, Phase 2, Phase 1115383-43-26741
Synonyms:
(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
(6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
.DELTA.1-6.alpha.-Methylhydrocortisone
1-Dehydro-6alpha-methylhydrocortisone
1-dehydro-6alpha-Methylhydrocortisone
1-dehydro-6α-methylhydrocortisone
11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione
11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
121673-01-6
4-08-00-03498 (Beilstein Handbook Reference)
46436_FLUKA
46436_RIEDEL
570-35-4
6 Methylprednisolone
6-Methylprednisolone
6-alpha-Methylprednisolone
6.alpha.-Methylprednisolone
6923-42-8
6alpha-Methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione
6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methylprednisolone
6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
83-43-2
AC1L1N7A
Artisone-Wyeth
Artisone-wyeth
BPBio1_000174
BRD-K35240538-001-03-1
BRN 2340300
BSPBio_000158
Besonia
Bio-0658
CHEBI:6888
CHEMBL650
CID6741
CPD000058330
D00407
D008775
DB00959
Depo-Medrol (acetate)
Dopomedrol
EINECS 201-476-4
Esametone
Firmacort
HMS1568H20
HMS2090B13
HSDB 3127
LMST02030178
LS-118498
Lemod
M0639_SIGMA
M1665
MEPRDL
MLS000028541
MLS001148159
MLS002207191
Medesone
Medixon
Medlone 21
 
Medrate
Medrol
Medrol (TN)
Medrol Adt Pak
Medrol Dosepak
Medrol adt pak
Medrol dosepak
Medrol, Solu-Medrol, Medrone, Methylprednisolone
Medrone
Mesopren
Metastab
Methyleneprednisolone
Methylprednisolon
Methylprednisolone
Methylprednisolone (JP15/USP/INN)
Methylprednisolone [USAN:INN:BAN:JAN]
Methylprednisolone, 6-alpha
Methylprednisolonum
Methylprednisolonum [INN-Latin]
Metilbetasone
Metilprednisolona
Metilprednisolona [INN-Spanish]
Metilprednisolone
Metilprednisolone [DCIT]
Metilprednisolone [Dcit]
Metipred
Metrisone
Metrocort
Metysolon
Moderin
MolPort-002-528-554
NCGC00022735-03
NCI60_001657
NSC-19987
NSC19987
Nirypan
Noretona
Predni N Tablinen
Prednol- L
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl- (8CI)
Prestwick0_000279
Prestwick1_000279
Prestwick2_000279
Prestwick3_000279
Prestwick_622
Promacortine
Reactenol
S1733_Selleck
SAM002589984
SMR000058330
SPBio_002377
Sieropresol
Solomet
Summicort
Suprametil
U 7532
UNII-X4W7ZR7023
Urbason
Urbasone
Wyacort
ZINC03875560
delta(1)-6alpha-Methylhydrocortisone
delta(sup 1)-6-alpha-Methylhydrocortisone
methylprednisolone
methylprenisolone
2
LenograstimapprovedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 11202135968-09-1
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
 
Granulocyte colony stimulating factor 3 (CHO cell derived)
Granulocyte colony-stimulating factor lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
3
Prednisoloneapproved, vet_approvedPhase 4, Phase 3, Phase 2, Phase 1115350-24-85755
Synonyms:
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
.DELTA.1-Cortisol
.DELTA.1-Dehydrocortisol
.DELTA.1-Dehydrohydrocortisone
.DELTA.1-Hydrocortisone
.delta.-Cortef
.delta.-Stab
1,2-Dehydrohydrocortisone
1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
1-Dehydrocortisol
1-Dehydrohydrocortisone
3,20-dioxo-11beta,17alpha,21-Trihydroxy-1,4-pregnadiene
46656_FLUKA
46656_RIEDEL
50-24-8
58201-11-9
8056-11-9
AC-1773
AC1L1L2E
Ak-Pred
Ak-Tate
Alphadrol
Articulose-50
BPBio1_000164
BRD-K98039984-001-03-0
BRN 1354103
BSPBio_000148
Bio-0666
Bubbli-Pred
C07369
CCRIS 980
CHEBI:8378
CHEMBL131
CID5755
CO-Hydeltra
CPD000718761
Co-Hydeltra
Codelcortone
Cordrol
Cortalone
Cotogesic
Cotolone
D00472
D011239
DB00860
Decaprednil
Decortin H
Delcortol
Delta F
Delta(1)-dehydrohydrocortisone
Delta-Cortef
Delta-Cortef (TN)
Delta-Ef-Cortelan
Delta-Stab
Delta-stab
Deltacortenol
Deltacortril
Deltacortril Enteric
Deltahydrocortisone
Deltasolone
Deltisilone
Depo-Medrol
Derpo PD
Derpo Pd
Dexa-Cortidelt Hostacortin H
Dexa-Cortidelt hostacortin H
Di Adreson F
Di-Adreson F
Di-Adreson-F
Di-adreson F
DiAdresonF
Dicortol
Donisolone
Dydeltrone
EINECS 200-021-7
Eazolin D
Econopred
Econopred Plus
Erbacort
Erbasona
Estilsona
Fernisolone
Fernisolone P
Fernisolone-P
Flamasone
HMS1568H10
HMS2090J05
HSDB 3385
Hostacortin H
Hydeltra
Hydeltra-Tba
Hydeltrasol
Hydeltrone
Hydrodeltalone
Hydrodeltisone
Hydroretrocortin
Hydroretrocortine
I-Pred
Inflamase Forte
Inflamase Mild
K 1557
Key-Pred
Klismacort
LMST02030179
LS-7669
Lentosone
Lite Pred
M-Predrol
 
MLS001304083
MLS002154250
MLS002207037
Medrol
Medrol Acetate
Metacortandralone
Methylprednisolone Acetate
Meti-Derm
Meticortelone
Metreton
MolPort-002-507-147
NCGC00179649-01
NSC 9120
NSC9120
NSC9900
Neo-Delta-Cortef
Nisolone
Nor-Pred T.B.A.
Ocu-Pred
Ocu-Pred Forte
Ophtho-Tate
Orapred
P0152_SIGMA
P0637
P6004_SIGMA
PRDL
PRED-G
Panafcortelone
Paracortol
Paracotol
Pediapred
Poly-Pred
Precortalon
Precortancyl
Precortilon
Precortisyl
Pred Forte
Pred Mild
Predair
Predair A
Predair Forte
Predalone 50
Predalone T.B.A.
Predate
Predate Tba
Predate-50
Predcor-25
Predcor-50
Predcor-Tba
Predisolone Sodium Phosphate
Predne-Dome
Prednelan
Predni-Dome
Prednicen
Predniliderm
Predniretard
Prednis
Prednisolona
Prednisolona [INN-Spanish]
Prednisolone (JP15/USP/INN)
Prednisolone (anhydrous)
Prednisolone Acetate
Prednisolone Sodium Phosphate
Prednisolone Tebutate
Prednisolone [INN:BAN:JAN]
Prednisolonum
Prednisolonum [INN-Latin]
Predonin
Predonine
Prelone
Prenolone
Prestwick0_000274
Prestwick1_000274
Prestwick2_000274
Prestwick3_000274
Prestwick_404
Rolisone
S1737_Selleck
SAM002264639
SMR000718761
SPBio_002367
Scherisolon
Solone
Steran
Sterane
Sterolone
Supercortisol
UNII-9PHQ9Y1OLM
Ulacort
Ultra Pred
Ultracorten H
Ultracortene H
Ultracortene-H
Ultracortene-Hydrogen
Ultracortene-hydrogen
ZINC03833821
component of Ataraxoid
component of K-Predne-Dome
delta(1)-Cortisol
delta(1)-Dehydrocortisol
delta(1)-Dehydrohydrocortisone
delta(1)-Hydrocortisone
delta(sup 1)-Cortisol
delta(sup 1)-Dehydrocortisol
delta(sup 1)-Dehydrohydrocortisone
delta(sup 1)-Hydrocortisone
delta-dehydrocortisol
delta-dehydrohydrocortisone
delta-hydrocortisone
prednisolone
4
FludarabineapprovedPhase 4, Phase 3, Phase 2, Phase 1111321679-14-1, 75607-67-930751
Synonyms:
(2R,3S,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
(2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
2-F-ARAA
2-F-ara-A
2-Fluoro Ara-A
2-Fluoro-9-beta-D-arabinofuranosyladenine
2-fluoro ARA-A
21679-14-1
9-beta-D-Arabinofuranosyl-2-fluoroadenine
9-beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine
9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro- (9CI)
AC1LCW8I
AC1Q51CF
C10H12FN5O4
CCRIS 3382
CHEMBL1568
CID657237
CPD000058874
D07966
EINECS 244-525-5
F-Ara-A
FAMP
FT-0082766
FaraA
Fludara
Fludara, Fludarabine
 
Fludarabina
Fludarabina [Spanish]
Fludarabine
Fludarabine (INN)
Fludarabine 5'-monophosphate
Fludarabine [INN]
Fludarabine monophosphate
Fludarabine phosphate
Fludarabinum
Fludarabinum [Latin]
Fludura
Fluradosa
Fluradosa (TN)
HSDB 6964
I14-4978
LS-15061
MLS000028687
NSC 118218
NSC 118218H
NSC-118218
S1491_Selleck
SAM002548956
SMR000058874
SQ Fludarabine
UNII-1X9VK9O1SC
UNII-P2K93U8740
ZINC04216238
5
ChlorambucilapprovedPhase 4, Phase 3, Phase 2, Phase 154305-03-32708
Synonyms:
23125_FLUKA
305-03-3
4-(P-Bis(beta-chloroethyl)aminophenyl)butyric acid
4-(p-bis(β-chloroethyl)aminophenyl)butyric acid
4-[p-[bis(2-chloroethyl)amino]phenyl]butyric acid
AB00051938
AC1L1EAB
AC1Q75DO
AI3-26083
Ambochlorin
Amboclorin
BPBio1_001208
BRD-K29458283-001-05-9
BRN 0999011
BSPBio_001098
BSPBio_001971
C 0253
C0253_SIGMA
C14H19Cl2NO2
CAS-305-03-3
CB 1348
CB-1348
CB1348
CCRIS 126
CHEBI:28830
CHEMBL515
CHLORAMBUCIL
CID2708
CPD000058372
Cb l348
Chlocambucil
Chloorambucol
Chlorambucil (USP/INN)
Chlorambucil [INN:BAN]
Chlorambucilum
Chlorambucilum [INN-Latin]
Chloraminophen
Chloraminophene
Chlorbutin
Chlorbutine
Chlorbutinum
Chloroambucil
Chlorobutin
Chlorobutine
Clorambucile
Clorambucile [DCIT]
Clorambucilo
Clorambucilo [INN-Spanish]
D00266
D002699
DB00291
DivK1c_000688
EINECS 206-162-0
EU-0100227
Ecloril
Elcoril
Elcorin
FT-0083565
Glaxo Wellcome Brand of Chlorambucil
GlaxoSmithKline Brand of Chlorambucil
HMS1571G20
HMS1920M15
HMS2090M19
HMS2091A22
HMS502C10
HSDB 3026
IDI1_000688
KBio1_000688
KBio2_000558
KBio2_003126
 
KBio2_005694
KBio3_001191
KBioGR_000766
KBioSS_000558
LEUKERAN (TN)
LS-1158
Leuk ersan
Leukeran
Leukeran Tablets
Leukeran tablets
Leukersan
Leukoran
Linfolizin
Linfolysin
Lopac-C-0253
Lopac0_000227
Lympholysin
MLS000028443
MLS001076130
MolPort-000-152-694
N,N-Di-2-chloroethyl-gamma-P-aminophenylbutyric acid
N,N-di-2-chloroethyl-γ-p-aminophenylbutyric acid
NCGC00015199-01
NCGC00015199-02
NCGC00015199-03
NCGC00015199-07
NCGC00015199-14
NCGC00023250-00
NCGC00023250-03
NCGC00023250-04
NCGC00023250-05
NCGC00023250-06
NCGC00023250-07
NCGC00023250-08
NCGC00023250-09
NCGC00023250-10
NCI-C03485
NCI60_002639
NINDS_000688
NSC 3088
NSC-3088
NSC3088
Pepstatin
Phenylbuttersaeure-lost
Phenylbuttersaeure-lost [German]
Phenylbutyric Acid Nitrogen Mustard
Phenylbutyric acid nitrogen mustard
Prestwick0_001079
Prestwick1_001079
Prestwick2_001079
Prestwick3_001079
RCRA waste no. U035
Rcra waste number U035
SAM002564202
SMR000058372
SPBio_000249
SPBio_002999
SPECTRUM1500171
ST50410766
Spectrum2_000065
Spectrum3_000336
Spectrum4_000273
Spectrum5_000677
Spectrum_000118
TL8002353
UNII-18D0SL7309
WLN: QV3R DN2G2G
Wellcome Brand of Chlorambucil
chlorambucil
gamma-[P-Di(2-chloroethyl)aminophenyl]butyric acid
γ-[p-di(2-chloroethyl)aminophenyl]butyric acid
6
MethotrexateapprovedPhase 4, Phase 3, Phase 2, Phase 115181959-05-2, 59-05-2126941
Synonyms:
4-amino-10-methylfolic acid
4-amino-N(10)-Methylpteroylglutamic acid
Abitrexate
Amethopterin
Amethopterine
Antifolan
Arbitrexate
Emtexate
Folex
HDMTX
L-Amethopterin
Ledertrexate
MTX
Metatrexan
 
Methopterin
Methotextrate
Methotrate
Methotrexat
Methotrexate Sodium
Methotrexatum
Methylaminopterin
Methylaminopterinum
Metotrexato
Mexate
Méthotrexate
N-Bismethylpteroylglutamic Acid
N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Rheumatrex
Trexall
7
rituximabapprovedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 11654174722-31-710201696
Synonyms:
AntiCD20
IDEC-102
IDEC-C2B8
 
Ig gamma-1 chain C region
MabThera
Mabthera
Rituxan
rituximab
8
ThiotepaapprovedPhase 4, Phase 3, Phase 2, Phase 121652-24-45453
Synonyms:
 
Thioplex
9
Adenosineapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 139758-61-760961
Synonyms:
(2R,3R,4S,5R)-2-(6-Aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
(2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
1-(6-Amino-9H-purin-9-yl)-1-deoxy-beta-D-Ribofuranose
1-(6-Amino-9H-purin-9-yl)-1-deoxy-beta-delta-Ribofuranose
1odi
2fqy
2gl0
30143-02-3
4-Aminopyrazolo[3,4-d]pyrimidine ribonucleoside
46946-45-6
46969-16-8
58-61-7
6-Amino-9-.beta.-ribofuranosyl-9H-purine
6-Amino-9-beta-D-ribofuranosyl-9H-purine
6-Amino-9beta-D-ribofuranosyl-9H-purine
6-Amino-9beta-delta-ribofuranosyl-9H-purine
9-(beta-D-Arabinofuranosyl)adenine
9-beta-D-Arabinofuranosyladenine
9-beta-D-Ribofuranosidoadenine
9-beta-D-Ribofuranosyl-9H-purin-6-amine
9-beta-D-Ribofuranosyladenine
9-beta-delta-Arabinofuranosyladenine
9-beta-delta-Ribofuranosidoadenine
9-beta-delta-Ribofuranosyl-9H-purin-6-amine
9-beta-delta-Ribofuranosyladenine
9beta-D-Ribofuranosyladenine
9beta-D-ribofuranosyl-9H-Purin-6-amine
9beta-delta-Ribofuranosyladenine
9beta-delta-ribofuranosyl-9H-Purin-6-amine
A0152
A4036_SIGMA
A9251_SIGMA
AC1L1U8O
AC1Q1ID3
AC1Q52XU
ADN
AI3-52413
Ade-Rib
Ade-rib
Adenin riboside
Adenine 9-beta-D-arabinofuranoside
Adenine deoxyribonucleoside
Adenine nucleoside
Adenine riboside
Adenine-9-beta-D-ribofuranoside
Adenine-9beta-D-Ribofuranoside
Adenine-9beta-delta-Ribofuranoside
Adenocard
Adenocard (TN)
Adenocard, Adenosine
Adenocor
Adenoscan
Adenoscan (TN)
Adenosin
Adenosin [German]
Adenosina
Adenosine (JAN/USP)
Adenosine [USAN:BAN]
Adenosine, homopolymer
Adenosinum
Adensoine
Adenyldeoxyriboside
Ado
Adénosine
BB_NC-0565
BSPBio_001796
Bio1_000437
 
Bio1_000926
Bio1_001415
Boniton
C00212
CCRIS 2557
CHEBI:16335
CHEMBL477
CID60961
Caswell No. 010B
D000241
D00045
DB00640
Deoxyadenosine
Desoxyadenosine
EA6C60C2-6AFB-4264-A2F0-541373DB950E
EINECS 200-389-9
FT-0082881
HMS1920A13
HMS2091G13
KBio3_001296
LS-15085
MEDR-640
MLS000069638
MLS002153227
MolPort-001-838-229
Myocol
NCGC00023673-03
NCGC00023673-04
NCGC00023673-05
NCGC00023673-06
NCGC00023673-07
NSC 627048
NSC 7652
NSC627048
NSC7652
Nucleocardyl
Pallacor
Polyadenosine
Polyriboadenosine
S1647_Selleck
SDCCGMLS-0003108.P003
SMR000058216
SPBio_001194
SPECTRUM1500107
SR 96225
SR-96225
SUN-Y4001
Sandesin
Spectrum2_001257
Spectrum3_000288
TL8003749
UNII-K72T3FS567
USAF CB-10
V0098
Vidarabine
ZINC02169830
adenine-D-ribose
adenosine
b-D-Adenosine
beta-Adenosine
beta-D-Adenosine
beta-D-Ribofuranoside, adenine-9
beta-delta-Adenosine
bmse000061
nchembio.143-comp9
nchembio.186-comp109
nchembio.2007.56-comp13
nchembio.64-comp4
nchembio706-5
10
VidarabineapprovedPhase 4, Phase 3, Phase 2, Phase 151224356-66-932326, 21704
Synonyms:
(+)-Cyclaradine
.beta.-Adenosine
.beta.-D-Adenosine
1odi
2-(6-AMINO-purin-9-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol
2946-52-3
2fqy
2gl0
30143-02-3
3080-29-3
3228-71-5
4005-33-8
46946-45-6
46969-16-8
524-69-6
5536-17-4
58-61-7
9-Arabinosyladenine
9-beta-D-Arabinofuranosyl-9H-purin-6-amine
9-beta-D-Arabinofuranosyl-adenine
9-beta-D-Arabinofuranosyladenine
9-beta-D-arabinofuranosyl-adenine
9-β-D-arabinofuranosyl-9H-purin-6-amine
9-β-D-arabinofuranosyladenine
A 9251
A0152
A4036_SIGMA
A4676_SIGMA
A5762_SIGMA
A9251_SIGMA
AC1L18OL
AC1L1U8O
AC1L2IWM
AC1L2SCM
AC1O4WIN
AC1O8PY7
AC1Q1ID3
AC1Q4Y1Z
AC1Q52XU
ADENOSINE, U.S.P.
ADN
AI3-52413
AI3-52821
AR-1H6029
ARA-A NSC 247519
Ade-Rib
Adenine Arabinoside
Adenine arabinoside
Adenine nucleoside
Adenine riboside
Adenine xyloside
Adenocard
Adenocard (TN)
Adenocard, Adenosine
Adenocor
Adenoscan
Adenoscan (TN)
Adenosin
Adenosin [German]
Adenosine (JAN/USP)
Adenosine [USAN:BAN]
Adenosine arabinose
Adenosine-8-14C
Adensoine
Ambap5536-17-4
Ara A
Ara-A
Ara-ATP
Araadenosine
Arabinoside Adenine
Arabinoside adenine
Arabinosyl Adenine
Arabinosyl adenine
Arabinosyl-adenine
Arabinosyladenine
Arasena-A
Armes
Armes (TN)
BB_NC-0565
BPBio1_000898
BRN 0624881
BSPBio_000816
BSPBio_001796
BSPBio_002000
Bio1_000437
Bio1_000926
Bio1_001415
Boniton
C00212
CAS-5536-17-4
CCRIS 2557
CCRIS 3383
CHEBI:136932
CHEBI:16335
CHEBI:45327
CHEMBL1090
CHEMBL20247
CHEMBL477
CI 673
CI-673
CID102198
CID191
CID21704
CID60961
CID6420052
CID6713976
CPD000471872
Caswell No. 010B
D000241
D00045
D06298
DB00640
DivK1c_000191
EINECS 200-389-9
EINECS 217-911-6
EINECS 226-893-9
EU-0100123
FT-0082881
HMS1570I18
HMS1920A13
HMS1921K05
HMS2090F06
HMS2091G13
HMS2092C16
HMS500J13
HSDB 6514
 
I01-1121
IDI1_000191
KBio1_000191
KBio2_002418
KBio2_004986
KBio2_007554
KBio3_001296
KBio3_001500
KBioGR_001224
KBioSS_002424
L000094
LS-15059
LS-15085
Lopac0_000123
MEDR-640
MLS000069638
MLS000699527
MLS001066352
MLS001333133
MLS001333134
MLS002153227
MLS002153992
MolPort-001-785-903
MolPort-001-838-229
MolPort-003-666-308
Myocol
NCGC00016656-01
NCGC00023673-03
NCGC00023673-04
NCGC00023673-05
NCGC00023673-06
NCGC00023673-07
NCGC00094579-01
NCGC00094579-02
NCGC00094579-03
NCGC00094579-04
NCGC00178869-01
NCGC00179417-01
NCI60_003823
NCI60_037192
NCIOpen2_003303
NCIOpen2_005376
NINDS_000191
NSC 247519
NSC 404241
NSC 627048
NSC 7359
NSC 7652
NSC-404241
NSC247519
NSC404241
NSC627048
NSC70422
NSC7359
NSC7652
NSC80832
NSC87676
NSC91041
Nucleocardyl
PDSP1_001036
PDSP2_001020
Pallacor
Polyadenosine
Polyriboadenosine
Prestwick0_000768
Prestwick1_000768
Prestwick2_000768
Prestwick3_000768
Prestwick_983
RAB
S1647_Selleck
S1784_Selleck
SAM002564191
SMP1_000312
SMR000058216
SMR000225041
SMR000471872
SMR001233326
SPBio_001194
SPBio_001491
SPBio_002755
SPECTRUM1500107
SPECTRUM1500609
SR 96225
SR-96225
STK361815
SUN-Y4001
Sandesin
Spectrum2_001257
Spectrum2_001336
Spectrum3_000288
Spectrum3_000580
Spectrum4_000782
Spectrum5_001429
Spectrum_001894
Spongoadenosine
TL8003749
UNII-3XQD2MEW34
UNII-K72T3FS567
USAF CB-10
V0098
VIRDARABINE
Vidarabin
Vidarabina
Vidarabina [DCIT]
Vidarabine
Vidarabine (JAN)
Vidarabine anhydrous
Vidarabinum
Vira ATM
Vira-A
Vira-A, Vidarabine
XA
Xylosyl A
Xylosyladenine
ZINC00970363
ZINC02169830
adenine-D-ribose
adenosine
alpha-Ara A
beta-Adenosine
beta-Ara A
beta-D-Adenosine
bmse000061
nchembio.143-comp9
nchembio.186-comp109
nchembio.64-comp4
nchembio706-5
11
Cyclophosphamideapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1282950-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Anhydrous cyclophosphamide
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
 
DB00531
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
12
Busulfanapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 154055-98-12478
Synonyms:
1, 4-Dimethanesulfonoxybutane
1, 4-Dimethylsulfonoxybutane
1, {4-Bis[methanesulfonoxy]butane}
1,4-BUTANEDIOL DIMETHANESULFONATE
1,4-Bis(methanesulfonoxy)butane
1,4-Bis(methanesulfonyloxy)butane
1,4-Bis[methanesulfonoxy]butane
1,4-Butanedi yl dimethanesulfonate
1,4-Butanediol dimethanesulfonate
1,4-Butanediol dimethanesulphonate
1,4-Butanediol dimethylsulfonate
1,4-Butanediol, dimethanesulfonate
1,4-Butanediol, dimethanesulphonate
1,4-Butanediyl dimethanesulfonate
1,4-Di(methylsulfonoxy)butane
1,4-Dimesyloxybutane
1,4-Dimethane sulfonyl oxybutane
1,4-Dimethanesulfonoxybutane
1,4-Dimethanesulfonoxylbutane
1,4-Dimethanesulfonyloxybutane
1,4-Dimethanesulphonyloxybutane
1,4-Dimethylsulfonoxybutane
1,4-Dimethylsulfonyloxybutane
2041 C. B
2041 C. B.
2041 C.B
2041 C.B.
4-((Methylsulfonyl)oxy)butyl methanesulfonate
4-methylsulfonyloxybutyl methanesulfonate
55-98-1
AC-198
AC1L1DRQ
AC1Q4GRQ
AI3-25012
AKOS003614975
AN 33501
Ambap55-98-1
B1022
B2635_FLUKA
B2635_SIGMA
BRN 1791786
BSPBio_001920
BUSULFAN (1,4-BUTANEDIOL, DIMETHANESULFONATE)
Bisulfex
Busilvex
Busulfan
Busulfan (JP15/USP/INN)
Busulfan GlaxoSmithKline Brand
Busulfan Orphan Brand
Busulfan Wellcome
Busulfan Wellcome Brand
Busulfan [INN:JAN]
Busulfano
Busulfano [INN-Spanish]
Busulfanum
Busulfanum [INN-Latin]
Busulfex
Busulphan
Busulphane
Butanedioldimethanesulfonate
Buzulfan
C.B. 2041
C6H14O6S2
CB 2041
CCRIS 418
CHEBI:28901
CHEMBL820
CID2478
CPD000058613
Citosulfan
D002066
D00248
DB01008
DivK1c_000847
EINECS 200-250-2
FT-0083567
G.T. 41
GT 2041
GT 41
Glaxo Wellcome Brand of Busulfan
GlaxoSmithKline Brand of Busulfan
Glyzophrol
HMS1920I07
HMS2091O09
HMS502K09
 
HSDB 7605
I09-1371
IDI1_000847
InChI=1/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3
KBio1_000847
KBio2_000512
KBio2_003080
KBio2_005648
KBio3_001420
KBioGR_000698
KBioSS_000512
LS-1358
Leucosulfan
MLS001076666
MYLERAN (TN)
Mablin
Methanesulfonic
Methanesulfonic acid, tetram ethylene ester
Methanesulfonic acid, tetramethylene ester
Mielevcin
Mielosan
Mielucin
Milecitan
Mileran
Misulban
Mitosan
Mitostan
MolPort-001-783-406
Myeleukon
Myeloleukon
Myelosan
Myelosanum
Mylecytan
Myleran
Myleran Tablets
Myleran tablets
Myleran, Busulfex, Busulfan
Mylerlan
NCGC00090905-01
NCGC00090905-02
NCGC00090905-03
NCGC00090905-04
NCGC00090905-05
NCGC00090905-06
NCGC00090905-07
NCI-C01592
NCI60_041640
NCIMech_000192
NINDS_000847
NSC 750
NSC-750
NSC-750sulphabutin
NSC750
Orphan Brand of Busulfan
Prestwick_989
S1692_Selleck
SAM002554887
SMR000058613
SPBio_000253
SPECTRUM1500152
ST50825921
Spectrum2_000067
Spectrum3_000320
Spectrum4_000259
Spectrum5_000928
Spectrum_000092
Sulfabutin
Sulfabutin (VAN)
Sulphabutin
Tetramethylene Dimethane Sulfonate
Tetramethylene bis(methanesulfonate)
Tetramethylene bis[methanesulfonate]
Tetramethylene dimethane sulfonate
Tetramethylene {bis[methanesulfonate]}
Tetramethylenester Kyseliny Methansulfonove
Tetramethylenester kyseliny methansulfonove
Tetramethylenester kyseliny methansulfonove [Czech]
UNII-G1LN9045DK
WLN: WS1&O4OSW1
Wellcome Brand of Busulfan
Wellcome, Busulfan
X 149
acid, tetramethylene ester
alkylating agent: crosslinks guanine residues
busulfan
butane-1,4-diyl dimethanesulfonate
n-Butane-1,3-di(methylsulfonate)
13
Pentostatinapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 15353910-25-140926, 439693
Synonyms:
(8R)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol
(8R)-3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7,8-dihydro-4H-imidazo[4,5-d][1,3]diazepin-8-ol
(R)-3-(2-Deoxy-.beta.-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo(4,5-d)(1,3)diazepin-8-ol
2'-DCF
2'-Deoxycoformycin
2'-Dexoycoformycin
53910-25-1
59979-24-7
AC1L97UQ
BIDD:GT0136
C02267
CHEBI:41829
CHEMBL1580
CI-825
CID439693
CL-67310465
CO-Vidarabine
Co-V
 
Co-vidarabine
Coforin
Covidarabine
D00155
DB00552
Deoxycoformycin
Nipent
Nipent (TN)
Oncopent
PD-81565
PD-ADI
Pentostatin
Pentostatin (JAN/USAN/INN)
Pentostatina
Pentostatine
Pentostatinum
Vidarbine
Vira A deaminase inhibitor
dCF
pentostatin
14
Valganciclovirapproved, investigationalPhase 4, Phase 280175865-60-864147
Synonyms:
175865-60-8
5-Amino-3-[1-(hydroxymethyl)-2-(L-valyloxy)ethoxymethyl]-6,7-dihydro-3H-imidazo[4,5-d]pyrimidin-7-one
AC1L20JF
AC1Q63EV
C14H22N6O5
CID64147
Cymeval
D02495
DB01610
I06-1704
L-Valine, 2-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)-3-hydroxypropyl ester
L-Valine, ester with ganciclovir
 
L-valine, ester with ganciclovir
LS-173677
NCGC00168779-01
RO1079070/194
RS 79070
UNII-GCU97FKN3R
Valcyt
Valcyte
Valganciclovir
Valganciclovir (INN)
Valganciclovir (Oral)
Valganciclovir [INN:BAN]
[2-[(2-amino-6-oxo-3H-purin-9-yl)methoxy]-3-hydroxypropyl] (2S)-2-amino-3-methylbutanoate
valganciclovir
15
MentholapprovedPhase 423532216-51-516666
Synonyms:
(−
()-Menthol
(+)-Neo-menthol
(+)-p-Menthan-3-ol
(+-)-(1R*,3R*,4S*)-Menthol
(+-)-Menthol
(+/-)-Menthol
(+/-)-p-Menthan-3-ol
(-)-(1R,3R,4S)-Menthol
(-)-Menthyl alcohol
(-)-menthol
(-)-p-Menthan-3-ol
(-)-trans-p-Menthan-cis-ol
(1R)-(-)-Menthol
(1R,2S,5R)-(-)-menthol
(1R,2S,5R)-Menthol
(1R,3R,4S)-(-)-MENTHOL
(1R,3R,4S)-(-)-Menthol
(1R-(1-alpha,2-beta,5-alpha))-5-Methyl-2-(1-methylethyl)cyclohexanol
(1S, 2S, 5R)-(+)-Neomenthol
(1S,2R,5R)-(+)-Isomenthol
(1S,2R,5S)-(+)-Menthol
(1S,2R,5S)-Menthol
(1alpha,2beta,5alpha)-5-Methyl-2(1-methylethyl)cyclohexanol
(1r,2s,5r)-(-)-menthol
(L)-MENTHOL
(R)-(-)-Menthol
(r)-(-)-menthol
)-Menthol
--MENTHOL
1-Menthol
1490-04-6
15356-60-2
15356-70-4
15785_RIEDEL
15785_SIAL
19863P
2-Isopropyl-5-methylcyclohexanol
20747-49-3
2216-51-5
3-p-Menthol
4-Isopropyl-1-methylcyclohexan-3-ol
491-02-1
5-Methyl-2-(1-methylethyl)-cyclohexanol
5-Methyl-2-(1-methylethyl)cyclohexanol
5-methyl-2-(propan-2-yl)cyclohexanol
5-methyl-2-propan-2-ylcyclohexan-1-ol
551376_ALDRICH
551376_FLUKA
588733_ALDRICH
613290_ALDRICH
613290_FLUKA
63660_FLUKA
63670_ALDRICH
63670_FLUKA
63975-60-0
6C6A4A8C-A054-468C-A1F0-F29E39838CF2
89-78-1
98167-53-4
AC1L1B2E
AC1L28FR
AC1Q1NQ2
AC1Q2QQM
AI3-08161
AI3-52408
AKOS000119740
AR-1J3337
BB_NC-0057
BRN 1902288
BRN 3194263
BSPBio_003062
C00400
C10H20O
CCRIS 3728
CCRIS 375
CCRIS 4666
CCRIS 9231
CHEBI:15409
CHEBI:545611
CHEMBL256087
CHEMBL470670
CID1254
CID16666
Caswell No. 540
D-(-)-Menthol
D-p-Menthan-3-ol
D00064
D008610
D04849
D04918
DB00825
DivK1c_000820
EINECS 201-939-0
EINECS 207-724-8
EINECS 216-074-4
EINECS 218-690-9
EINECS 239-387-8
EINECS 239-388-3
EPA Pesticide Chemical Code 051601
FEMA No. 2665
Fisherman's friend lozenges
Fisherman's friend lozenges (TN)
HMS1922G13
HMS2092L14
HMS502I22
 
HSDB 5662
HSDB 593
Headache crystals
Hexahydrothymol
I06-1216
I14-7371
IDI1_000820
KBio1_000820
KBio2_000785
KBio2_003353
KBio2_005921
KBio3_002562
KBioSS_000785
L-(-)-Menthol
L-(-)-menthol
L-Menthol
L-menthol
LMPR0102090001
LS-2353
LS-57201
LS-886
LS-89531
LS-89533
Levomenthol
Levomenthol [INN:BAN]
Levomentholum
Levomentholum [INN-Latin]
Levomentol
M0321
M0545
M2772_SIAL
MENTHOL
MLS002207256
Menthacamphor
Menthol
Menthol (USP)
Menthol (VAN)
Menthol natural
Menthol natural, brazilian
Menthol racemic
Menthol racemique
Menthol racemique [French]
Menthol solution
Menthol, (1alpha,2beta,5alpha)-Isomer
Menthomenthol
Menthyl alcohol
MolPort-000-849-729
MolPort-001-793-392
NCGC00159382-02
NCGC00159382-03
NCGC00164247-01
NCGC00164247-02
NCI-C50000
NINDS_000820
NOOLISFMXDJSKH-KXUCPTDWBX
NSC 2603
NSC 62788
NSC2603
NSC62788
Neoisomenthol
Peppermint camphor
RACEMIC MENTHOL U.S.P.
Racementhol
Racementhol [INN:BAN]
Racementholum
Racementholum [INN-Latin]
Racementol
Racementol [INN-Spanish]
Racemic menthol
Robitussin Cough Drops
SDCCGMLS-0066659.P001
SMR001306785
SPBio_000869
SPECTRUM1503134
STK802468
Spectrum2_000855
Spectrum3_001561
Spectrum5_001060
Spectrum_000305
Tra-kill tracheal mite killer
U.S.P. Menthol
U.S.p. Menthol
UNII-BZ1R15MTK7
UNII-L7T10EIP3A
UNII-YS08XHA860
W266507_ALDRICH
W266523_ALDRICH
W266590_ALDRICH
WLN: L6TJ AY1&1 BQ D1
WLN: L6TJ AY1&1 DQ D1 -L
ZINC01482164
cis-1 ,3-trans-1,4-(+-)-menthol
cis-1,3-trans-1,4-(+-)-menthol
d,l-Menthol
d-Menthol
d-Neomenthol
dl-3-p-Menthanol
dl-Menthol
dl-Menthol (JP15)
l-(-)-Menthol
l-Menthol
l-Menthol (JP15)
l-Menthol (TN)
l-Menthol (natural)
nchembio862-comp1
p-Menthan-3-ol
rac-Menthol
16
Folic Acidapproved, nutraceutical, vet_approvedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1427959-30-36037
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
AI3-26387
AKOS000503224
ARONIS014410
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
Antianemia factor
Apo-Folic
BIDD:ER0563
BIDD:GT0641
BIF0608
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
FOL
Facid
Factor U
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
Folsaeure
 
Folsan
Folsaure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
Incafolic
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
LS-2157
Liver Lactobacillus casei factor
MLS001304016
MLS001335861
Millafol
Mission prenatal
Mittafol
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-Pteroyl-L-glutamic acid
N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
NINDS_000494
NSC 3073
Nifolin
Nifolin [Denmark]
Novofolacid
Novofolacid [Canada]
PGA
PGA (VAN)
Prestwick3_000627
Prestwick_230
PteGlu
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylglutamate
Pteroylglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
SMP2_000137
SMR000471860
SPBio_001357
SPECTRUM1502020
Serum Folate Level
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
Spectrum_001381
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin B9
Vitamin Bc
Vitamin Be
Vitamin M
bmse000299
folic acid
nchembio.108-comp10
17glucocorticoidsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 14920
18Dermatologic AgentsPhase 4, Phase 3, Phase 2, Phase 15674
19Autonomic AgentsPhase 4, Phase 3, Phase 2, Phase 19774
20Folic Acid AntagonistsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 12200
21Gastrointestinal AgentsPhase 4, Phase 3, Phase 2, Phase 18109
22Nucleic Acid Synthesis InhibitorsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 14855
23Prednisolone phosphatePhase 4, Phase 3, Phase 2, Phase 11153
24Protective AgentsPhase 4, Phase 3, Phase 2, Phase 17190
25Vitamin B ComplexPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 14229
26
TreosulfanPhase 4, Phase 3, Phase 232299-75-29296
Synonyms:
(2S,3S)-Threitol 1,4-bismethanesulfonate
1,4-Dimethanesulfonate(2S,3S)-Threitol
1,4-DimethanesulfonateL-(+ )-Threitol
1,4-DimethanesulfonateL-Threitol
DHB
Dihydroxybusulfan
 
Dihydroxymyleran
L-Threitol 1,4-dimethanesulfonate
L-Threitol, 1, 4-bis(methanesulfonate)
L-Threitol-1, 4-bis(methanesulfonate)
L-Threitol-1,4-bis(methanesulfonate)
L-Threityl dimesylate
Tresulfan
27Prednisolone hemisuccinatePhase 4, Phase 3, Phase 2, Phase 11153
28Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 2, Phase 122776
29Methylprednisolone HemisuccinatePhase 4, Phase 3, Phase 2, Phase 11153
30Neuroprotective AgentsPhase 4, Phase 3, Phase 2, Phase 11672
31Antineoplastic Agents, HormonalPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 15407
32Methylprednisolone acetatePhase 4, Phase 3, Phase 2, Phase 11153
33Prednisolone acetatePhase 4, Phase 3, Phase 2, Phase 11153
34Imatinib MesylatePhase 4, Phase 3, Phase 2, Phase 1594123596
35Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 112767
36Anti-Infective AgentsPhase 4, Phase 3, Phase 2, Phase 121402
37Antiviral AgentsPhase 4, Phase 3, Phase 2, Phase 19732
38Bendamustine HydrochloridePhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1260
39HormonesPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 113979
40Immunosuppressive AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 112770
41Anti-Inflammatory AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 110355
42Alkylating AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 14694
43Antineoplastic Agents, AlkylatingPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 14474
44Antirheumatic AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 110627
45AntimetabolitesPhase 4, Phase 3, Phase 2, Phase 111774
46Hormone AntagonistsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 112778
47HematinicsPhase 4, Phase 3, Phase 2, Phase 11630
48Antilymphocyte SerumPhase 4, Phase 3, Phase 2, Phase 1399
49Antimetabolites, AntineoplasticPhase 4, Phase 3, Phase 2, Phase 17171
50AntiemeticsPhase 4, Phase 3, Phase 2, Phase 13888

Interventional clinical trials:

(show top 50)    (show all 1919)
idNameStatusNCT IDPhase
1Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.Unknown statusNCT00131313Phase 4
2Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In RemissionUnknown statusNCT01901666Phase 4
3Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin AmericaCompletedNCT02559583Phase 4
4Antiviral Treatment of Chronic Lymphocytic LeukemiaCompletedNCT01255644Phase 4
5A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe)CompletedNCT01056510Phase 4
6A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or ThrombocytopeniaCompletedNCT00220311Phase 4
7Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL)CompletedNCT00802737Phase 4
8A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic StatusCompletedNCT01271010Phase 4
9A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Patients With Chronic Lymphocytic Leukemia and Unfavourable Somatic StatusCompletedNCT01283386Phase 4
10The Duration of Humoral Immunity and the Memory Cell Function After Vaccination With 7-valent Pneumococcal Conjugate Vaccine in CLLCompletedNCT00919321Phase 4
11Effect of Epoetin Alfa on Hemoglobin, Symptom Distress, and Quality of Life in Patients Receiving ChemotherapyCompletedNCT00524407Phase 4
12Bone Marrow Transplantation in Treating Patients With Hematologic CancerCompletedNCT00003398Phase 4
13Low Grade LymphomaRecruitingNCT01698866Phase 4
14Rituximab (RTX) Therapy in Patients With Active TAORecruitingNCT02378298Phase 4
15ALL SCTped FORUM - Pharmacogenomic Study (add-on Study)RecruitingNCT02670564Phase 4
16A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin BTerminatedNCT02608060Phase 4
17A Study of Safety and Effectiveness of Bendamustine Hydrochloride in Adult Filipino Patients With Chronic Lymphocytic LeukemiaWithdrawnNCT01739491Phase 4
18Trial of FFP+HDMP+Rituximab for Ultra-high Risk Chronic Lymphocytic LeukemiaUnknown statusNCT01670812Phase 3
19Bendamustine Hydrochloride Injection for Previously Untreated Chronic Lymphocytic LeukemiaUnknown statusNCT01657955Phase 3
20Chlorambucil in Treating Patients With Advanced Chronic Lymphocytic LeukemiaUnknown statusNCT00017108Phase 3
21The Effect of 25-OH-Vitamin-D3 Substitution in Patients With Malignant and Immune-hematologic DiseasesUnknown statusNCT01518959Phase 3
2230Gy Versus 40Gy Involved-field Radiotherapy for Localized Diffuse Large B Cell Lymphoma Achieving CR After ChemotherapyUnknown statusNCT01156259Phase 3
23Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin LymphomaUnknown statusNCT00551239Phase 3
24Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With CancerUnknown statusNCT00482716Phase 3
25Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and NeutropeniaUnknown statusNCT00020865Phase 3
26Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic PainUnknown statusNCT01316744Phase 3
27Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic SyndromeUnknown statusNCT00002989Phase 3
28Thymoglobulin in Unrelated Hematopoietic Progenitor Cell TransplantationUnknown statusNCT01217723Phase 3
29Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's LymphomaUnknown statusNCT00003338Phase 2, Phase 3
30Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's LymphomaUnknown statusNCT00003337Phase 3
31Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile NeutropeniaUnknown statusNCT00445497Phase 3
32Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's LymphomaUnknown statusNCT00003639Phase 3
33Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's LymphomaUnknown statusNCT00003924Phase 3
34Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete RemissionUnknown statusNCT00382109Phase 3
35Unrelated Double Umbilical Cord Blood Units TransplantationUnknown statusNCT01015742Phase 2, Phase 3
36Fludarabine With or Without Cyclophosphamide in Treating Patients With Advanced Chronic Lymphocytic LeukemiaCompletedNCT00276848Phase 3
37Autologous Stem Cell Transplantation in Chronic Lymphocytic LeukemiaCompletedNCT00931645Phase 3
38Fludarabine or Observation in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic LeukemiaCompletedNCT00262782Phase 3
39Fludarabine or Chlorambucil as First-Line Therapy in Treating Older Patients With Previously Untreated Chronic Lymphocytic LeukemiaCompletedNCT00262795Phase 3
40Bendamustine Versus Fludarabine in Chronic Lymphocytic Leukemia (CLL)CompletedNCT01423032Phase 2, Phase 3
41Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic LeukemiaCompletedNCT01500083Phase 3
42Fludarabine and Darbepoetin Alfa in Treating Older Patients With Chronic Lymphocytic LeukemiaCompletedNCT00281892Phase 3
43A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)CompletedNCT01580228Phase 3
44A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)CompletedNCT01539512Phase 3
45Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) PatientsCompletedNCT00086580Phase 3
46A Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (RESONATE™-2)CompletedNCT01722487Phase 3
47FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed PatientsCompletedNCT00090051Phase 3
48Fludarabine, Cyclophosphamide, and Rituximab Followed by Rituximab or Observation in Older Patients With Previously Untreated B-Cell Chronic Lymphocytic LeukemiaCompletedNCT00645606Phase 3
49Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaCompletedNCT00024440Phase 3
50Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic LeukemiaCompletedNCT00275054Phase 3

Search NIH Clinical Center for Chronic Lymphocytic Leukemia

Inferred drug relations via UMLS68/NDF-RT46:

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Chronic Lymphocytic Leukemia cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Chronic Lymphocytic Leukemia:
Blood stem cell transplantation for hematological diseases
Hematopoietic stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Chronic Lymphocytic Leukemia:
Peripheral blood-derived hematopoietic stem cells (family)
Bone marrow-derived hematopoietic stem cells


Cochrane evidence based reviews: leukemia, lymphocytic, chronic, b-cell

Genetic Tests for Chronic Lymphocytic Leukemia

About this section

Genetic tests related to Chronic Lymphocytic Leukemia:

id Genetic test Affiliating Genes
1 Chronic Lymphocytic Leukemia27 24
2 Leukemia, Chronic Lymphocytic24 CCND1

Anatomical Context for Chronic Lymphocytic Leukemia

About this section

MalaCards organs/tissues related to Chronic Lymphocytic Leukemia:

36
B cells, Bone, Bone marrow, T cells, Myeloid, Lymph node, Testes

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Chronic Lymphocytic Leukemia:
id TissueAnatomical CompartmentCell Relevance
1 BloodHematopoietic Bone MarrowHematopoietic Stem Cells Potential therapeutic candidate
2 BloodPeripheral BloodMature B-Cells Affected by disease
3 BloodHematopoietic Bone MarrowSmall Pre B-Cells Affected by disease

Publications for Chronic Lymphocytic Leukemia

About this section

Articles related to Chronic Lymphocytic Leukemia:

(show top 50)    (show all 2723)
idTitleAuthorsYear
1
From genome to proteome: Looking beyond DNA and RNA in chronic lymphocytic leukemia. (28069558)
2017
2
Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: Implication for therapy. (28053325)
2017
3
High-resolution melting analysis for rapid and sensitive NOTCH1 screening in chronic lymphocytic leukemia. (28075457)
2017
4
Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. (28049639)
2017
5
PPAR-delta promotes survival of chronic lymphocytic leukemia cells in energetically unfavorable conditions. (28050012)
2017
6
Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. (28073846)
2017
7
Synthetic high-density lipoproteins as targeted monotherapy for chronic lymphocytic leukemia. (28061439)
2017
8
Chronic Lymphocytic Leukemia Prognostic Index: A New Integrated Scoring System to Predict the Time to First Treatment in Chinese Patients with Chronic Lymphocytic Leukemia. (28091403)
2017
9
Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia. (28077600)
2017
10
State of the Art in MicroRNA as Diagnostic and Therapeutic Biomarkers in Chronic Lymphocytic Leukemia. (28084621)
2017
11
Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment. (28088788)
2017
12
Refractory pure red cell aplasia associated with chronic lymphocytic leukemia successfully treated with ibrutinib. (27756158)
2017
13
Indirect Treatment Comparisons of Ibrutinib Versus Physician's Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia. (28062113)
2017
14
The Expression of Toll-Like Receptors in Patients with B-Cell Chronic Lymphocytic Leukemia. (28083607)
2017
15
Cytochrome P450 Allele CYP3A7*1C Associates with Adverse Outcomes in Chronic Lymphocytic Leukemia, Breast, and Lung Cancer. (26964624)
2016
16
Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia. (27661115)
2016
17
Composite hairy cell leukemia and chronic lymphocytic leukemia. (27685932)
2016
18
lncRNA profiling in early-stage chronic lymphocytic leukemia identifies transcriptional fingerprints with relevance in clinical outcome. (27611921)
2016
19
Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations. (27633522)
2016
20
HIF-1I+ regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment. (26825709)
2016
21
Response to ibrutinib of refractory life-threatening autoimmune hemolytic anemia occurring in a relapsed chronic lymphocytic leukemia patient with 17p deletion. (26999572)
2016
22
Differential expression, localization and activity of MARCKS between mantle cell lymphoma and chronic lymphocytic leukemia. (27662204)
2016
23
Spleen Tyrosine Kinase Is Involved in the CD38 Signal Transduction Pathway in Chronic Lymphocytic Leukemia. (28036404)
2016
24
Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for Chronic Lymphocytic Leukemia. (27456945)
2016
25
Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors. (27198719)
2016
26
A Novel Assay for the Identification of NOTCH1 PEST Domain Mutations in Chronic Lymphocytic Leukemia. (28074183)
2016
27
Integration of innate into adaptive immune responses in ZAP-70-positive chronic lymphocytic leukemia. (26508782)
2016
28
Real--world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: Data from 95 consecutive patients treated in a compassionate use program. (27198718)
2016
29
Neoadjuvant Vismodegib Before Mohs: Lack of Tissue Sparing and Squamous Differentiation of Basal Cell Carcinoma in a Patient With Chronic Lymphocytic Leukemia. (27153042)
2016
30
COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status. (27185377)
2016
31
Innate lymphoid cells are expanded and functionally altered in chronic lymphocytic leukemia. (27662009)
2016
32
Renal insufficiency is an independent prognostic factor in patients with chronic lymphocytic leukemia. (27634202)
2016
33
Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity. (27182988)
2016
34
Malakoplakia of the Urinary Bladder in a Patient with Chronic Lymphocytic Leukemia Under Ibrutinib Therapy: A Case Report. (27630324)
2016
35
A rare association of chronic lymphocytic leukemia with c-ANCA-positive Wegener's granulomatosis: a case report. (27183987)
2016
36
Reprogramming Nurse-like Cells with Interferon I^ to Interrupt Chronic Lymphocytic Leukemia Cell Survival. (27226587)
2016
37
The Importance of an In-depth Study of Immunoglobulin Gene Rearrangements When Ascertaining the Clonal Relationship between Concomitant Chronic Lymphocytic Leukemia and Multiple Myeloma. (28082975)
2016
38
Variation in the use of up-front chemotherapy for indolent B-cell lymphomas and chronic lymphocytic leukemia. (27982452)
2016
39
EBV-positive Richter's syndrome with laboratory features of Burkitt's lymphoma, in Ibrutinib-treated chronic lymphocytic leukemia. (27852142)
2016
40
Autoimmune hemolytic anemia (AIHA) associated with chronic lymphocytic leukemia in the current era of targeted therapy. (27657651)
2016
41
Cryoglobulinemia in a patient with chronic lymphocytic leukemia - A case report and review of literature of renal involvement in CLL. (27519936)
2016
42
Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes. (27198052)
2016
43
Epstein-Barr virus-positive diffuse large B cell lymphoma arising from a chronic lymphocytic leukemia: Overlapping features with classical Hodgkin lymphoma. (27170210)
2016
44
The expression of endothelin-1 in chronic lymphocytic leukemia is controlled by epigenetic mechanisms and extracellular stimuli. (28092772)
2016
45
Posttranscriptional upregulation of p53 by reactive oxygen species in chronic lymphocytic leukemia. (27634759)
2016
46
The histone methyltransferase EZH2 as a novel prosurvival factor in clinically aggressive chronic lymphocytic leukemia. (27191993)
2016
47
Downregulation of miR-15a and miR-16-1 at 13q14 in Chronic Lymphocytic Leukemia. (26908869)
2016
48
Increased risk of axial fractures in patients with untreated chronic lymphocytic leukemia: a population-based analysis. (27662013)
2016
49
Membranoproliferative glomerulonephritis and acute renal failure in a patient with chronic lymphocytic leukemia: Response to obinutuzumab. (27352257)
2016
50
Autocrine Signaling by Wnt-5a Deregulates Chemotaxis of Leukemic Cells and Predicts Clinical Outcome in Chronic Lymphocytic Leukemia. (26240275)
2016

Variations for Chronic Lymphocytic Leukemia

About this section

Copy number variations for Chronic Lymphocytic Leukemia from CNVD:

6 (show top 50)    (show all 1219)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1140421103366560104230405LossChronic lymphocytic leukemia
2148951110954839111582296LossChronic lymphocytic leukemia
3149471111421057111642223LossChronic lymphocytic leukemia
4154561115719205117399077LossChronic lymphocytic leukemia
5172061141510591145121245DeletionChronic lymphocytic leukemia
6172071141510591145121245LossChronic lymphocytic leukemia
7185271146265358148164994GainChronic lymphocytic leukemia
8197581151208615155645185GainChronic lymphocytic leukemia
9200251152611898157344161LossChronic lymphocytic leukemia
10213781158336749159355008LossChronic lymphocytic leukemia
11213841158391645159433573LossChronic lymphocytic leukemia
12213851158391645189498990LossChronic lymphocytic leukemia
13230231170758115170759115LossChronic lymphocytic leukemia
14230301170822660170823660GainChronic lymphocytic leukemia
15236261172107770172108770GainChronic lymphocytic leukemia
16241711176708253177307399GainChronic lymphocytic leukemia
17252741186459864186720923LossChronic lymphocytic leukemia
18253591187890295188217703LossChronic lymphocytic leukemia
19254351189143434189363313GainChronic lymphocytic leukemia
20254731189804292192389810GainChronic lymphocytic leukemia
21256851193314169193528753GainChronic lymphocytic leukemia
22267891202768030203457313LossChronic lymphocytic leukemia
23268181203067017205298659LossChronic lymphocytic leukemia
24269751204424298206588789LossChronic lymphocytic leukemia
25280761218313329220732423LossChronic lymphocytic leukemia
26281301218942571219164038LossChronic lymphocytic leukemia
27281331218959043244561923LossChronic lymphocytic leukemia
28282651220678511222112407GainChronic lymphocytic leukemia
29283211221304071221582122GainChronic lymphocytic leukemia
30285771223594083225234079LossChronic lymphocytic leukemia
31286431224353010225571533LossChronic lymphocytic leukemia
32287021224857883233411748LossChronic lymphocytic leukemia
33290661227299711227518155LossChronic lymphocytic leukemia
34291131227696842233631743LossChronic lymphocytic leukemia
35292651229664393229947546GainChronic lymphocytic leukemia
36295011232707626233302391LossChronic lymphocytic leukemia
373105312494371226054939LossChronic lymphocytic leukemia
383119312598512129490451DeletionChronic lymphocytic leukemia
393142512750448428494376LossChronic lymphocytic leukemia
403244313678354438823237LossChronic lymphocytic leukemia
413349514560698946307302GainChronic lymphocytic leukemia
423401615154576553346467LossChronic lymphocytic leukemia
433425515402976955100800LossChronic lymphocytic leukemia
443491115771209258034742GainChronic lymphocytic leukemia
453537916269708863142732LossChronic lymphocytic leukemia
463540616333597463596958GainChronic lymphocytic leukemia
473540716333597463641668GainChronic lymphocytic leukemia
483649717636456376710672LossChronic lymphocytic leukemia
493689018234186682576806LossChronic lymphocytic leukemia
503689518258123582812961LossChronic lymphocytic leukemia

Expression for genes affiliated with Chronic Lymphocytic Leukemia

About this section
Search GEO for disease gene expression data for Chronic Lymphocytic Leukemia.

Pathways for genes affiliated with Chronic Lymphocytic Leukemia

About this section

GO Terms for genes affiliated with Chronic Lymphocytic Leukemia

About this section

Cellular components related to Chronic Lymphocytic Leukemia according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1external side of plasma membraneGO:000989710.5CD5, FCER2, IGHG1, IGHM, MS4A1, P2RX7

Biological processes related to Chronic Lymphocytic Leukemia according to GeneCards Suite gene sharing:

(show all 18)
idNameGO IDScoreTop Affiliating Genes
1B cell receptor signaling pathwayGO:005085311.2BCL2, CD38, IGHG1, IGHM, ZAP70
2apoptotic signaling pathwayGO:009719011.2CD38, CD5, P2RX7
3cellular response to DNA damage stimulusGO:000697411.2ATM, BCL2, BCL3, CCND1, TP53
4determination of adult lifespanGO:000834011.2ATM, TP53
5mitotic G1 DNA damage checkpointGO:003157111.2CCND1, TP53
6DNA damage response, signal transduction by p53 class mediatorGO:003033011.2BCL3, TP53
7intrinsic apoptotic signaling pathway in response to DNA damageGO:000863011.2ATM, BCL2, MCL1
8humoral immune responseGO:000695911.2BCL2, MS4A1, PAX5
9negative regulation of anoikisGO:200081111.2BCL2, MCL1
10negative regulation of telomerase activityGO:005197411.1POT1, TP53
11negative regulation of apoptotic processGO:004306611.1BCL2, BCL3, CD38, MCL1, TP53
12negative regulation of bone resorptionGO:004577911.1CD38, P2RX7
13oocyte developmentGO:004859911.1ATM, BCL2
14regulation of apoptotic processGO:004298111.0ATM, BCL2, BCL3, IKZF3, TP53
15replicative senescenceGO:009039911.0ATM, TP53
16regulation of mitochondrial membrane permeabilityGO:004690211.0BCL2, TP53
17response to cytokineGO:003409710.9BCL2, CD38, MCL1
18response to gamma radiationGO:001033210.5BCL2, TP53, TRIM13

Molecular functions related to Chronic Lymphocytic Leukemia according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1channel activityGO:001526711.3BCL2, P2RX7
2BH3 domain bindingGO:005143411.3BCL2, MCL1
3protein bindingGO:000551510.6ATM, BCL2, BCL3, CCND1, CD5, FCER2

Sources for Chronic Lymphocytic Leukemia

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet